A Study to Evaluate the Intratumoral Influenza Vaccine Administration in Patients With Breast Cancer

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

September 28, 2025

Primary Completion Date

September 28, 2026

Study Completion Date

September 28, 2027

Conditions
Breast CancerBreast Cancer Triple Negative
Interventions
BIOLOGICAL

Fluzone Quadrivalent

Successive cohorts of participants (3 participants per tumor type per cohort) will each be started on a fixed dose of the influenza vaccine. For the first cohort, patients will receive Fluzone Quadrivalent - (Sanofi Pasteur) - 60mcg/0.5mL (standard dose IT flu shot, or dose level 0) intratumorally on day -6 +/- 1 day and day 0 or 1. For the second cohort, patients will receive Fluzone High-Dose Quadrivalent - (Sanofi Pasteur) - 240mcg/0.7mL (high dose IT flu shot, or dose level 1) intratumorally on day -6 +/- 1 day and day 0 or 1. has context menu

Trial Locations (1)

60612

Rush University Medical Center, Chicago

All Listed Sponsors
lead

Rush University Medical Center

OTHER